Boehringer Ingelheim's Spevigo Approved for GPP in India
By Rediff Money Desk, New Delhi May 15, 2024 16:15
Boehringer Ingelheim receives approval for Spevigo (Spesolimab), a first-in-class treatment for Generalised Pustular Psoriasis (GPP) flares in adults in India.
New Delhi, May 15 (PTI) Drug firm Boehringer Ingelheim on Wednesday said the domestic drug regulator has approved a medication Generalised Pustular Psoriasis (GPP) flares in adults.
The company has received approval from the Central Drugs Standard Control Organisation (CSDCO) for Spevigo (Spesolimab) injection, a first-in-class treatment for GPP flares in adults, Boehringer Ingelheim said in a statement.
In India, GPP presents a significant healthcare challenge, affecting individuals of all ages and demographics. While precise prevalence data for GPP in India is limited, GPP is widely recognised as a rare disease.
"The approval of SPEVIGO by the CDSCO represents a significant milestone in GPP management in India and underscores our commitment to bringing novel therapies into the country," Boehringer Ingelheim India Managing Director Gagandeep Singh Bedi stated.
Spevigo's impact goes beyond treatment; it's about giving patients the chance to reclaim their lives, he added.
"It presents a promising opportunity for enhancing effective management, quality of life, and patient outcomes in India, instilling hope for individuals grappling with GPP," Bedi said.
The company has received approval from the Central Drugs Standard Control Organisation (CSDCO) for Spevigo (Spesolimab) injection, a first-in-class treatment for GPP flares in adults, Boehringer Ingelheim said in a statement.
In India, GPP presents a significant healthcare challenge, affecting individuals of all ages and demographics. While precise prevalence data for GPP in India is limited, GPP is widely recognised as a rare disease.
"The approval of SPEVIGO by the CDSCO represents a significant milestone in GPP management in India and underscores our commitment to bringing novel therapies into the country," Boehringer Ingelheim India Managing Director Gagandeep Singh Bedi stated.
Spevigo's impact goes beyond treatment; it's about giving patients the chance to reclaim their lives, he added.
"It presents a promising opportunity for enhancing effective management, quality of life, and patient outcomes in India, instilling hope for individuals grappling with GPP," Bedi said.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- IFL Enterprises
- 1.36 (+ 4.62)
- 139837616
- Franklin Industries
- 3.90 (+ 4.56)
- 41704768
- Vodafone Idea L
- 16.28 ( -3.04)
- 37101580
- Sawaca Business Mach
- 0.67 ( -4.29)
- 36642255
- Tata Teleservices (M
- 97.43 (+ 19.80)
- 21113173
MORE NEWS
Sensex Hits 81,000, Nifty at Record 24,800: IT...
The Indian stock market continued its record-breaking run, with Sensex crossing 81,000...
World's Largest Coal Mines: India's SECL Holds...
Two coal blocks in India's South Eastern Coalfields (SECL) rank among the world's 10...
Infosys Q1 Profit Up 7.1%, Raises FY25 Outlook...
Infosys reported a 7% rise in Q1 net profit and raised its FY25 revenue growth guidance...